News

News
July 22, 2020

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
News
18 June, 2020

Our COVID-19 research Project supported by the French Government

Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
News
April 6, 2020

COVID-19, GNS561’s Assault begins in France !

Marseille, April 6, 2020 — Genoscience Pharma Starts a phase 2 multicenter study using GNS561,…
Read More
News
January 13, 2020

ISO9001:2015 Certification for our R&D and Clinical Activities in Oncology

Marseille, January 13, 2020 - Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and…
Read More
News
December 16, 2019

GNS561 to treat pancreas or colorectal cancer with liver metastasis

GENOSCIENCE PHARMA Announces Extension of GNS561 Phase 1/2 Clinical Trial to Patients with Pancreas or…
Read More
News
November 14, 2019

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor

Outstanding Data on GNS561 in Combination with a PD-1 Inhibitor to Be Presented at the…
Read More
News
September 25, 2019

Invest in the Future of Health Biotech, European Biotech Week

Invest in the Future of Health Biotech during the European Biotech Week 2019 (Brussels)  …
Read More
News
June 3, 2019

S.A.B Meeting in Chicago, during ASCO 2019

Scientific Advisory Board Meeting during ASCO 2019   Chicago, USA, June 3, 2019 — Genoscience…
Read More
News
April 17, 2019

Chaim Hurvitz, New Board of Directors Member

Chaim Hurvitz, New Board of Directors Member   Chaim Hurvitz has joined  Genoscience Pharma Board…
Read More
News
December 10, 2018

Most Innovative European Biotech SME for 2018

Most Innovative European Biotech SME for 2018   Bruxelles, Belgium, December 3, 2018 - Company…
Read More